<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04753775</url>
  </required_header>
  <id_info>
    <org_study_id>Rif. 1836/11.03.10</org_study_id>
    <nct_id>NCT04753775</nct_id>
  </id_info>
  <brief_title>RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF ENEMA ALOE VERA GEL IN ACTIVE ULCERATIVE PROCTOSIGMOIDITIS.</brief_title>
  <official_title>RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF ENEMA ALOE VERA GEL FOR ACHIVING REMISSION IN ACTIVE ULCERATIVE PROCTOSIGMOIDITIS.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ospedale Sandro Pertini, Roma</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ospedale Sandro Pertini, Roma</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Aloe vera is used for the treatment of inflammatory bowel disease (IBD), but no data are&#xD;
      present in regard the gel formulation as topical therapy in active ulcerative colitis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      44 ulcerative colitis (UC) patients were enrolled and randomly allocated to treatment for 4&#xD;
      weeks with oral mesalazine (800 mg three times daily) and enema (60 ml aloe vera gel) 1/day&#xD;
      (n = 22, Group A) or enema (60 ml placebo) (n = 22, Group B).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 10, 2010</start_date>
  <completion_date type="Actual">May 10, 2010</completion_date>
  <primary_completion_date type="Actual">April 10, 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>randomized controlled trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>22 patients were assigned to Group-A (5-ASA oral 800mg x 3 / day + 1 enema 60ml Aloe Vera gel / day) and 22 patients to Group-B (5-ASA oral 800mg x 3 / day + enema 60ml 1 Placebo / day).</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>endoscopic remission</measure>
    <time_frame>4 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">44</enrollment>
  <condition>Aloe Vera Gel, Proctosigmoiditis, Remission, Trial, Ulcerative Colitis (UC)</condition>
  <arm_group>
    <arm_group_label>22 patients were assigned to Group-A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>22 patients were assigned to Group-A</description>
  </arm_group>
  <arm_group>
    <arm_group_label>22 patients were assigned to Group-B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>22 patients were assigned to Group-B</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aloe vera gel</intervention_name>
    <arm_group_label>22 patients were assigned to Group-A</arm_group_label>
    <arm_group_label>22 patients were assigned to Group-B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  age over 18 years, mild to moderate active ulcerative proctosigmoiditis, diagnosed for&#xD;
             the first time and no therapy started before. The maximum extension of the disease was&#xD;
             accepted of 40-60 cm from the anal verge or distal disease.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  an extension of disease above the sigma, renal impairment, pregnancy, lactation or&#xD;
             established low compliance&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 9, 2021</study_first_submitted>
  <study_first_submitted_qc>February 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 15, 2021</study_first_posted>
  <last_update_submitted>February 9, 2021</last_update_submitted>
  <last_update_submitted_qc>February 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ospedale Sandro Pertini, Roma</investigator_affiliation>
    <investigator_full_name>Roberta Pica</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colitis, Ulcerative</mesh_term>
    <mesh_term>Proctocolitis</mesh_term>
    <mesh_term>Ulcer</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

